Kepler Capital Markets Reiterates “€88.00” Price Target for Sanofi (EPA:SAN)

Kepler Capital Markets set a €88.00 ($102.33) target price on Sanofi (EPA:SAN) in a research report released on Friday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.

A number of other research analysts also recently commented on the stock. Oddo Bhf set a €94.00 ($109.30) price objective on shares of Sanofi and gave the company a buy rating in a research note on Tuesday, July 30th. Jefferies Financial Group set a €90.00 ($104.65) price objective on shares of Sanofi and gave the company a buy rating in a research note on Friday, June 21st. Sanford C. Bernstein set a €95.00 ($110.47) price objective on shares of Sanofi and gave the company a buy rating in a research note on Tuesday, September 3rd. Credit Suisse Group set a €82.00 ($95.35) price objective on shares of Sanofi and gave the company a buy rating in a research note on Tuesday, July 30th. Finally, Goldman Sachs Group set a €81.00 ($94.19) price objective on shares of Sanofi and gave the company a neutral rating in a research note on Monday, August 5th. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Sanofi has a consensus rating of Buy and a consensus price target of €87.27 ($101.47).

EPA SAN opened at €79.09 ($91.97) on Friday. Sanofi has a 12 month low of €63.09 ($73.36) and a 12 month high of €92.97 ($108.10). The company’s fifty day moving average is €76.45.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Further Reading: Outperform Rating

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.